Medline MDLN 深 沪
等待开盘 08-21 09:30:00 美东时间
32.58
-1.330
-3.92%
华盛通- 最 高34.19
- 今 开33.95
- 成交量 669.94万股
- 最 低 32.485
- 昨 收 33.91
- 总市值 428.33亿
- 52周最高 50.8762
- 市盈率 静 22.83
- 换手率 0.51%
- 52周最低 32.485
- 委 比 99.46%
- 总股本 13.15亿
- 历史最高 50.8762
- 量 比 1.24
- 振 幅 5.03%
- 历史最低 32.485
- 每 手 1
- 风险率 4.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Reported Earlier, FDA Says Medline Issued Correction For Convenience Kits Containing B. Braun Bupivacaine Hydrochloride Components, Identified As Most Serious Recall Type; B. Braun Reported 35 Serious Injuries, No Deaths
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/convenience-kit-recall-medline-issues-correction-convenience-kits-containing-b-braun-bupivacaine
今天 03:19
Medline Convenience Kits Impacted By Contamination In Recalled Becton Dickinson Products
The U.S. Food and Drug Administration (FDA) alerted healthcare providers regarding Medline Inc. (NASDAQ:MDLN) convenience kits containing recalled antiseptic applicators manufactured by Becton, Dickinson and Company (NYSE:BDX). The regulatory warning follows corrective measures by Medline to address...
08-14 02:00
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
凯雷Q2重仓医疗用品巨头Medline(MDLN.US)和航空维修巨头StandardAero(SARO.US) 建仓AI新云厂商Nebius(NBIS.US)
根据美国证券交易委员会(SEC)披露，全球另类资产管理巨头凯雷(CARLYLE GROUP INC)递交了截止至2026年6月30日的第二季度持仓报告(13F)。
08-10 17:18
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
财报速睇 | Medline 2026财年Q2营收76.85亿美元，同比增长11.6%；归母净利润0.60亿美元，同比下滑82.0%
华盛资讯8月6日讯，Medline公布2026财年Q2业绩，公司Q2营收76.85亿美元，同比增长11.6%，归母净利润0.60亿美元，同比下滑82.0%。
08-06 05:05
Medline shares are trading lower despite reporting better-than-expected Q2 financial results. The decline may be related to a softer adjusted EBITDA outlook, as management cited higher-than-expected inflationary pressures stemming from the Middle East conflict.
Medline shares are trading lower despite reporting better-than-expected Q2 financial results. The decline may be related to a softer adjusted EBITDA outlook, as management cited higher-than-expected inflationary pressures stemming from the Middle East conflict.
08-06 00:35
财报速睇 | Medline 2026财年Q2营收76.85亿美元，同比增长11.6%；归母净利润0.60亿美元，同比下滑82.0%
华盛资讯8月5日讯，Medline公布2026财年Q2业绩，公司Q2营收76.85亿美元，同比增长11.6%，归母净利润0.60亿美元，同比下滑82.0%。
08-05 19:46
Medline Q2 Adj. EPS $0.50 Beats $0.32 Estimate, Sales $7.685B Beat $7.512B Estimate
Medline (NASDAQ:MDLN) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.32 by 56.25 percent. The company reported quarterly sales of $7.685 billion which beat the analyst consensus estimate of $7.512 billion by 2.30 percent.
08-05 19:33
